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Diffusion imaginga b s t r a c t
Background and purpose: Glioblastoma exhibits profound intratumoral heterogeneity in perfusion.
Particularly, low perfusion may induce treatment resistance. Thus, imaging approaches that define low
perfusion compartments are crucial for clinical management.
Materials and methods: A total of 112 newly diagnosed glioblastoma patients were prospectively recruited
for maximal safe resection. The apparent diffusion coefficient (ADC) and relative cerebral blood volume
(rCBV) were calculated from diffusion and perfusion imaging, respectively. Based on the overlapping
regions of lowest rCBV quartile (rCBVL) with the lowest ADC quartile (ADCL) and highest ADC quartile
(ADCH) in each tumor, two low perfusion compartments (ADCH-rCBVL and ADCL-rCBVL) were identified
for volumetric analysis. Lactate and macromolecule/lipid levels were determined from multivoxel MR
spectroscopic imaging. Progression-free survival (PFS) and overall survival (OS) were analyzed using
Kaplan–Meier’s and multivariate Cox regression analyses, to evaluate the effects of compartment volume
and lactate level on survival.
Results: Two compartments displayed higher lactate and macromolecule/lipid levels compared to con-
tralateral normal-appearing white matter (each P < 0.001). The proportion of the ADCL-rCBVL compart-
ment in the contrast-enhancing tumor was associated with a larger infiltration on FLAIR (P < 0.001,
rho = 0.42). The minimally invasive phenotype displayed a lower proportion of the ADCL-rCBVL compart-
ment than the localized (P = 0.031) and diffuse phenotypes (not significant). Multivariate Cox regression
showed higher lactate level in the ADCL-rCBVL compartment was associated with worsened survival (PFS:
HR 2.995, P = 0.047; OS: HR 4.974, P = 0.005).
Conclusions: Our results suggest that the ADCL-rCBVL compartment may potentially indicate a clinically
measurable resistant compartment.
 2019 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 134 (2019) 17–24Glioblastoma is a highly aggressive primary brain malignancy in
adults [1]. Despite advances in treatment, the median overall sur-
vival (OS) of patients remains low at 14.6 months [2]. Inconsistent
response is a major challenge in treatment and could be caused by
the extensive heterogeneity of this malignancy. Many genetically
distinct cell populations can exist in the same tumor and display
diverse treatment response [3,4].One of the most fundamental traits of glioblastoma is the
tumor-related angiogenesis and elevated perfusion, associated
with a more invasive phenotype [5]. However, a potent angiogen-
esis inhibitor failed to demonstrate consistent benefits in clinical
trials of de novo glioblastoma [6]. One possible explanation is the
profound intratumor perfusion heterogeneity in glioblastomas,
which is due to aberrant microvasculature and inefficient nutrient
delivery. This heterogeneity can give rise to regions within tumors
where the demand and supply of nutrients is mismatched [7].
Consequently, the sufficiently perfused habitats may hold the
advantages for progression and proliferation, whereas the
18 Low Perfusion Compartments in Glioblastomainsufficiently perfused habitats may harbor a more acidic microen-
vironment than other tumor sub-regions [8], which may preferen-
tially induce resistant clones to adjuvant therapy [9]. There is a
rising need to understand the function of low perfusion compart-
ments and evaluate their effects on treatment resistance.
Current clinical practice infers the low perfusion regions as the
non-enhancing regions within contrast enhancement on post-
contrast images, which can lead to non-specific results using con-
ventional weighted images [10,11]. Recent studies suggested that
quantitative imaging features are useful in reflecting intratumor
habitats and tumor microenvironment [12,13]. As such, multipara-
metric imaging may allow a more comprehensive evaluation of the
low perfusion compartments compared to the morphological
heterogeneity visualized by structural magnetic resonance imag-
ing (MRI).
The purpose of this study was to propose a method for quanti-
fying low perfusion compartments in glioblastoma using multi-
parametric MRI and habitat imaging, and investigate their effects
on treatment response and patient outcome. Our hypothesis is that
multiparametric MRI may facilitate the identification of clinically
relevant intratumor habitats that correlate with patient prognosis.
We integrated perfusion, diffusion and MR spectroscopic imag-
ing with conventional imaging in our study. The relative cerebral
blood volume (rCBV) calculated from perfusion imaging measures
tumor vascularity [14]. The apparent diffusion coefficient (ADC)
calculated from diffusion imaging provides information about
tumor microstructure by measuring diffusivity of water molecules
[15]. We used a thresholding method to visualize two low perfu-
sion compartments with high/low diffusivity. Thus, two low perfu-
sion compartments, distinguished by two potentially distinct
properties, were visualized: one compartment with restricted dif-
fusivity that may represent a sub-region with more microstructure
adapting to the acidic conditions [12], and one compartment with
increased diffusivity that may represent a sub-region with dimin-
ishing microstructure. We studied the metabolic signatures in each
compartment using MR spectroscopy. Using multivariate survival
analysis, we demonstrated that the volume and lactate level of
these two compartments are clinically important.Materials and methods
Patient cohort
Patients with a radiological diagnosis of primary supratentorial
glioblastoma suitable for maximal safe surgical resection were
prospectively recruited from July 2010 to April 2015. All patients
had a good performance status (World Health Organization perfor-
mance status 0–1). Exclusion criteria included history of previous
cranial surgery or radiotherapy/chemotherapy, or inability to
undergo MRI scanning. This study was approved by the local insti-
tutional review board. Signed informed consent was obtained from
all patients.
A total of 131 patients were recruited for the imaging scanning.
After surgery, non-glioblastomas were excluded and 112 patients
were included for regions of interest (ROI) analysis. Subgroups of
patients with available MRS data (58 patients), DTI invasive pheno-
type data (64 patients) and survival data (80 patients) were ana-
lyzed. Patient recruitment and subgroups were summarized in
Supplementary Fig. 1.Treatment and response evaluation
All patients were on stable doses (8 mg/day) of dexamethasone.
Tumor resection was performed with the guidance of neuronaviga-
tion (StealthStation, Medtronic) and 5-aminolevulinic acid fluores-
cence with other adjuvants, e.g., cortical and subcortical mapping,awake surgery, and intraoperative electrophysiology, to allow for
maximal safe resection. Extent of resection was assessed according
to the postoperative MRI scans within 72 hours as complete resec-
tion, partial resection of contrast-enhancing tumor or biopsy [16].
Patients received adjuvant therapy post-operatively according
to their performance status. All patients were followed up accord-
ing to the criteria of response assessment in neuro-oncology
(RANO) [17], incorporating clinical and radiological criteria.
Survivals were analyzed retrospectively in some cases when pseu-
doprogression was suspected if new contrast enhancement
appeared within first 12 weeks after completing
chemoradiotherapy.MRI acquisition
All MRI scans were performed at a 3-Tesla MRI system (Mag-
netron Trio; Siemens Healthcare, Erlangen, Germany) with a stan-
dard 12-channel receive-head coil. MRI sequences included: axial
T2-weighted, axial T2-weighted fluid-attenuated inversion recov-
ery (FLAIR), diffusion tensor imaging (DTI) with inline ADC calcula-
tion, multivoxel 2D 1H-MR spectroscopic imaging (MRSI), dynamic
susceptibility contrast (DSC) and post-contrast T1-weighted 3D
volumetric sequence. Scanning parameters are detailed in Supple-
mentary materials.Image processing
For each subject, all images were co-registered to T2-weighted
images with an affine transformation, using the linear image regis-
tration tool functions [18] in Oxford Centre for Functional MRI of
the Brain Software Library (FSL) v5.0.0 (Oxford, UK) [19].
DSC was processed and leakage correction was performed using
NordicICE (NordicNeuroLab, Bergen, Norway). The arterial input
function was automatically defined and rCBV was calculated. DTI
images were processed with the diffusion toolbox in FSL [20], dur-
ing which normalization and eddy current correction were per-
formed. The isotropic component (p) and anisotropic component
(q) were calculated using previous equations [21].
2D 1H-MRSI were processed using LCModel (Provencher, Oak-
ville, Ontario) and the concentrations of lactate (Lac) and macro-
molecule and lipid levels at 0.9 ppm (ML9) were calculated as a
ratio to creatine (Cr). The quality and reliability of MRSI, and all
spectra were evaluated using previous criteria [22].Regions of interest and volumetric analysis
Tumor Regions of interest (ROIs) were manually segmented in
3D slicer v4.6.2 (https://www.slicer.org/) [23] by a neurosurgeon
(, >7 years of experience) and a researcher (, >4 years of
brain tumor image analysis experience) and reviewed by a neuro-
radiologist (, >8 years of experience) on post-contrast T1W and
FLAIR images using a consistent criteria in each patient, and then
cross-validated by comparing the similarity of the delineation
using Dice similarity coefficient scores, blinded to the patient out-
comes. The contrast-enhancing (CE) ROI was defined as all abnor-
malities within the contrast-enhancing rim on the post-contrast
T1W images. FLAIR ROI was defined as the hyperintense abnormal-
ities on FLAIR images. The interrater variability was tested using
Dice similarity coefficient scores. For each individual patient, ROIs
of normal-appearing white matter (NAWM) were manually seg-
mented from the contralateral white matter as normal control. This
region was typically 10 mm in diameter and located in the white
matter which was furthest in distance from the tumor location
and has no perceivable abnormalities [24]. All parametric maps
of ADC and rCBV were normalized by the mean value in NAWM.
C. Li et al. / Radiotherapy and Oncology 134 (2019) 17–24 19ADC-rCBV ROIs were generated using quartile values in
MATLAB (v2016a, The MathWorks, Inc., Natick MA) from the CE
ROI. The procedure is illustrated in Fig. 1. Firstly, ADC and rCBV val-
ues were obtained from each voxel within the CE ROI and pooled
together as described previously [24]. The lowest quartile of the
pooled rCBV values (rCBVL) were interpreted as low perfusion
regions. Then the first quartile (ADCL) and last quartile (ADCH) of
ADC map were respectively overlaid on rCBVL maps. Finally, two
intersections of ADCL-rCBVL and ADCH-rCBVL ROIs were obtained.
Other regions within CE outside the two ADC-rCBV ROIs were
taken as abnormal controls (CE control, CEC). Absolute volumes
of ROIs were calculated in FSL [19]. Proportional volumes (%) of
two ADC-rCBV ROIs were calculated as the ratio of the absolute
volumes to CE volume.MRSI voxel selection
Due to the difference in spatial resolution between MRSI and
MRI, voxels from T2-weighted MRIs were projected onto MRSI
using MATLAB, to evaluate the spectroscopic measure of the
ADC-rCBV compartments identified on T2 space. The proportions
of the voxels of the ADC-rCBV compartments occupying each MRSI
voxel was calculated, and only the MRSI voxels that were com-
pletely within the delineated tumor were included in further anal-
yses. Since the ADC-rCBV compartments potentially included
multiple MRSI voxels, the proportions of T2-space voxels in the
MRSI voxels were calculated and taken as the weight of each MRSI
voxel. The sum weighted value was used as the final metabolic
value, providing an objective method for MRSI voxel selection
(Supplementary Fig. 2).DTI invasive phenotypes
We investigated DTI invasive phenotypes of 64 patients which
overlap with a previously reported cohort and have been corre-Fig. 1. Illustration of the pipeline to identify two ADC-rCBV compartments. Both ADC a
segmented manually. Low perfusion regions are partitioned using a quartile threshold. Si
respectively. The spatial overlap between the thresholded rCBV and ADC maps define
analyses of both compartments are performed and interrogated in invasive phenotype alated to isocitrate dehydrogenase (IDH) mutation status [25]. Three
invasive phenotypes (Supplementary Fig. 3) were classified using
previously described criteria [26] based on the decomposition of
diffusion tensor into isotropic (p) and anisotropic components
(q): (a) diffuse invasive phenotype; (b) localized invasive pheno-
type; and (c) minimal invasive phenotype.Statistical analysis
All analyses were performed with RStudio v3.2.3. Continuous
variables were tested with Welch Two Sample t-test. MRSI data
or tumor volume, were compared with Wilcoxon’s rank sum test
or Kruskal–Wallis’ rank sum test, as appropriate, using
Benjamini–Hochberg’s procedure for controlling the false discov-
ery rate in multiple comparisons. Spearman’s rank correlation
was used to model the relation between the volume of two ADC-
rCBV ROIs and the volume of CE and FLAIR ROIs. Survival was ana-
lyzed on patients who received standard treatment following
Stupp’s protocol. Kaplan–Meier’s using log-rank test and Cox pro-
portional hazards regression analyses were performed to evaluate
patient survival. For Kaplan–Meier’s analysis, the volumes of ROIs
and MRSI variables were dichotomized using the ‘surv_cutpoint’
function in R Package ‘‘survminer”. Patients who were alive in last
follow-up were censored. Multivariate Cox regression with for-
ward and backward stepwise procedures was performed, account-
ing for relevant covariates, including IDH-1 mutation, MGMT
promoter methylation status, sex, age, extent of resection and
contrast-enhancing tumor volume. The forward procedure started
from the model with one covariate. The backward procedure initi-
ated from the model including all covariates. For each step, Akaike
Information Criterion was used to evaluate the model perfor-
mance. The final multivariate model was constructed using the
covariates selected by the stepwise procedures. The hypothesis of
no effect was rejected at a two-sided level of 0.05.nd rCBV maps are co-registered to the T2 weighted images and tumor regions are
milarly, two ADC regions are partitioned using high and low ADC quartile thresholds
d two compartments ADCH-rCBVL and ADCL-rCBVL. MR volumetric and metabolic
nd patient survival analysis models.
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Patients
The mean age of the 112 patients included was 59.4 years
(range 22–76, 84 males; Table 1). Depending on the post-
operative status, patients received concurrent temozolomide
chemoradiotherapy followed by adjuvant temozolomide following
the Stupp protocol (73.2%, 82/112), short-course radiotherapy
(17.0%, 19/112), or best supportive care (9.8%, 11/112), respec-
tively. Eighty of 82 (97.6%) patients who received treatment fol-
lowing Stupp’s protocol had data available for survival analysis.
The median progression-free survival (PFS) was 265 days (range
25–1130 days) and overall survival was 455 days (range 52–
1376 days).Multiparametric MRI identified two low perfusion compartments
The volumes of ROIs for patient subgroups are compared in
Table 1. The interrater variability of the ROIs showed excellent
agreement, with Dice scores of 0.85 ± 0.10 (CE) and 0.86 ± 0.10
(FLAIR) respectively. The ADCH-rCBVL compartment (volume
5.7 ± 4.6 cm3) was generally larger than the ADCL-rCBVL compart-
ment (volume 2.3 ± 2.2 cm3) (P < 0.001). Completely resected
tumors had smaller CE volume (P = 0.006) and smaller ADCH-
rCBVL compartment (P = 0.002). Fig. 2(A, D) shows the two com-
partments for two cases.Low perfusion compartments displayed abnormal metabolic
signatures
The ADCH-rCBVL compartment showed a significantly higher
lactate/creatine (Lac/Cr) ratio than NAWM (P < 0.001), and an
increased ML9/Cr ratio compared to NAWM (P < 0.001). Similarly,
the ADCL-rCBVL compartment displayed higher Lac/Cr ratio and
ML9/Cr ratio than NAWM (both P < 0.001). Although not signifi-
cant, the Lac/Cr and ML9/Cr ratios in the ADCH-rCBVL compartment
were higher than the ADCL-rCBVL compartment (Supplementary
Table 1). Fig. 2 shows the comparison of the metabolite levels of
two compartments.Table 1
Patient clinical characteristics and volumes of regions of interest.
Variables Patient number CE FLAIR
Mean ± SD (cm3) P Mean ± SD (
Age at diagnosis
<60 38 41.9 ± 24.0 0.022 101.4 ± 55.4
60 74 58.6 ± 35.7 119.5 ± 63.8
Sex
Male 84 54.5 ± 34.1 0.323 115.2 ± 62.8
Female 28 48.5 ± 30.0 107.7 ± 57.8
Extent of resection
Complete 75 45.8 ± 26.0 0.006 106.0 ± 58.0
Partial 37 67.4 ± 40.8 128.3 ± 66.1
MGMT promoter methylation status*
Methylated 48 48.4 ± 32.7 0.154 105.4 ± 66.3
Unmethylated 60 55.8 ± 32.1 121.1 ± 57.9
IDH-1 mutation status
Mutant 7 54.6 ± 35.4 0.895 102.2 ± 69.1
Wild-type 105 52.9 ± 33.1 114.1 ± 61.2
Bold values: P < 0.05
* MGMT promoter methylation status unavailable for 4 patients. cm: centimeters; CE
abnormalities visualized on fluid-attenuated inversion recovery images; ADCL-rCBVL: o
overlapping regions of highest ADC quartile and lowest rCBV quartile; IDH-1: Isocitrate d
deviation.Low perfusion compartments exhibited diverse effects on tumor
invasion
The contrast-enhancing (CE) tumor volume was significantly
correlated with the Lac/Cr ratio in the ADCL-rCBVL (P = 0.018,
rho = 0.34). Interestingly, the volume of tumor infiltration beyond
contrast enhancement, which was delineated on FLAIR images
and normalized by CE volume, showed a moderate positive corre-
lation with the proportional volume of the ADCL-rCBVL compart-
ment (P < 0.001, rho = 0.42) and a negative correlation with the
proportional volume of the ADCH-rCBVL compartment (P < 0.001,
rho = 0.32). The correlations of ROI volumes are demonstrated
in Supplementary Fig. 4.
The ADCL-rCBVL compartment of minimally invasive tumors showed
lower lactate
The minimally invasive phenotype displayed a lower propor-
tional volume of ADCL-rCBVL compartment in CE ROI than the
localized (P = 0.031) and diffuse phenotype (not significant), and
a higher proportion of ADCH-rCBVL compartment than the local-
ized (P = 0.024) and diffuse phenotype (not significant), suggesting
the effects of the two low perfusion compartments to tumor inva-
siveness were different. Of note, the minimally invasive phenotype
displayed lower Lac/Cr ratio compared to the localized (P = 0.027)
and diffuse phenotype (P = 0.044), indicating that the ADCL-rCBVL
compartment may have less acidic microenvironment in the min-
imally invasive tumors. A full comparison between the three inva-
sive phenotypes can be found in Supplementary Table 2.Low perfusion compartments exhibited diversity in treatment response
First, we used multivariate Cox regression to analyze all rele-
vant clinical covariates. The results showed that extent of resection
(EOR) (PFS: hazard ratio [HR] = 2.825, P = 0.003; OS: HR = 2.063,
P = 0.024), CE tumor volume (OS: HR = 2.311, P < 0.001) and FLAIR
tumor volume (OS: HR = 0.653, P = 0.031) were significantly associ-
ated with survivals.
Next, we included the volumes of two compartments and their
Lac/Cr ratios into the survival models. The results using a stepwise
procedure showed that higher volumes of the two compartments
were associated with better PFS (ADCH-rCBVL: HR = 0.102,ADCH-rCBVL ADCL-rCBVL
cm3) P Mean ± SD (cm3) P Mean ± SD (cm3) P
0.143 4.3 ± 3.7 0.020 1.9 ± 1.6 0.224
6.3 ± 4.8 2.5 ± 2.4
0.675 5.8 ± 4.6 0.657 2.4 ± 2.3 0.328
5.4 ± 4.4 1.9 ± 1.8
0.062 4.8 ± 3.9 0.002 2.1 ± 1.8 0.685
7.5 ± 5.2 2.6 ± 2.8
0.161 4.8 ± 4.1 0.099 2.2 ± 2.4 0.282
6.1 ± 4.5 2.4 ± 2.0
0.471 5.8 ± 4.9 0.843 2.2 ± 1.7 0.787
5.6 ± 4.6 2.3 ± 2.2
: regions including all the abnormalities within contrasting enhancing rim; FLAIR:
verlapping regions of lowest ADC quartile and lowest rCBV quartile; ADCH-rCBVL:
ehydrogenase1; MGMT: O-6-methylguanine-DNA methyltransferase; SD: Standard
Fig. 2. Two hypoxic compartments and MRS characteristics. Case 1: A–C; Case 2: D–F. A & D show the location of ADCL-rCBVL (yellow) and ADCH-rCBVL (blue) compartments.
B & E demonstrate the Lac/Cr ratios of the two compartments. C & F demonstrate the ML9/Cr ratios in the two compartments. The color bar show the level of metabolites (red:
high, blue: low). Note that case 1 shows greater tumor volume and higher lactate level. G & H demonstrate the MRSI characteristics of the compartments over the patient
cohort. Yellow: ADCL-rCBVL; blue: ADCH-rCBVL; black: contrast-enhancing control (CEC); gray: normal-appearing white matter (NAWM). G: mean Lac/Cr level; H: mean ML9/
Cr. ***P < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Cr ratio in the two compartments was associated with worse PFS
(ADCH-rCBVL: HR = 6.562, P = 0.002; ADCL-rCBVL: HR = 2.995,
P = 0.047). Further, the higher Lac/Cr ratio in the ADCL-rCBVL com-
partment was also associated with worse OS (HR = 4.974,
P = 0.005). In contrast, the Lac/Cr ratio in the contrast-enhancing
control regions was associated with better survivals (PFS:
HR = 0.053, P = 0.001; OS: HR = 0.090, P = 0.007). The results of
the Cox proportional hazards models are described in Table 2
and the Kaplan–Meier curves using log-rank test are shown in
Fig. 3.
Discussion
This study combined perfusion and diffusion parameters to
quantify the low perfusion compartments that may be responsiblefor treatment resistance. The non-invasive approach using physio-
logical imaging may potentially improve the commonly used
weighted structural imaging.
The clinical values of the individual markers have been assessed
previously. Among them, rCBV is reported to indicate IDH muta-
tion status and associated with hypoxia-initiated angiogenesis
[27]. Decreased ADC reflects restricted diffusivity, which is consid-
ered to represent higher tumor cellularity/cell packing [28] and
associated with shorter survival [29]. Of note, although another
meta-analysis also showed that the ADC value had an inverse cor-
relation with cellularity in glioma, this correlation was not consis-
tent in all tumor types [30]. Here we integrated multiparametric
MRI to identify two low perfusion compartments. With similar
low levels of perfusion, the restricted diffusivity in the ADCL-
rCBVL compartment suggests this compartment may contain more
microstructures, compared to the ADCH-rCBVL compartment.
Table 2
Multivariate and Stepwise modeling of patient survivals.
Factors PFS OS
Multivariate Stepwise Multivariate Stepwise
HR 95%CI P HR 95%CI P HR 95%CI P HR 95%CI P
Age 1.007 0.979–1.035 0.645 1.002 0.971–1.033 0.911 0.927 0.860–0.998 0.045
Sex (M) 1.499 0.838–2.681 0.172 5.043 1.063–23.91 0.042 1.252 0.662–2.365 0.490
EOR (partial resection) 2.825 1.417–5.635 0.003 4.531 1.002–20.49 0.050 2.063 1.099–3.874 0.024 12.18 2.701–54.91 0.001
MGMT promoter methylation status* 0.624 0.366–1.063 0.083 0.392 0.125–1.233 0.109 0.647 0.358–1.167 0.148 0.231 0.070–0.762 0.016
IDH-1 mutation status 0.902 0.278–2.926 0.864 0.900 0.256–3.170 0.870
CE volume 1.291 0.861–1.935 0.216 6.760 0.696–65.63 0.099 2.311 1.527–3.499 <0.001 3.080 1.487–6.383 0.002
FLAIR volume 0.775 0.519–1.157 0.212 2.008 0.818–4.926 0.128 0.653 0.444–0.961 0.031
ADCL-rCBVL volume 0.184 0.039–0.874 0.033
ADCH-rCBVL volume 0.102 0.011–0.992 0.049
Lac/Cr in ADCH-rCBVL 6.562 2.023–21.29 0.002 2.367 0.825–6.790 0.109
Lac/Cr in ADCL-rCBVL 2.995 1.012–8.861 0.047 4.974 1.608–15.39 0.005
Lac/Cr in CEC 0.053 0.010–0.295 0.001 0.090 0.016–0.520 0.007
Bold values: P < 0.05
* MGMT-methylation status unavailable for 4 patients. EOR: extent of resection. PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence
interval; IDH-1: Isocitrate dehydrogenase1; MGMT: O-6-methylguanine-DNA methyltransferase; CE: regions including all the abnormalities within contrasting enhancing
rim; FLAIR: abnormalities visualized on fluid-attenuated inversion recovery images; Lac: lactate; Cr: creatine; ADCL-rCBVL: overlapping regions of lowest ADC quartile of and
lowest rCBV quartile; ADCH-rCBVL: overlapping regions of highest ADC quartile and lowest rCBV quartile; CEC: contrast enhanced control.
Fig. 3. Kaplan–Meier’s plots of survival analysis. Log-rank tests show larger proportional volume of ADCL-rCBVL compartment is associated with better PFS (P = 0.041) (A),
while higher Lac/Cr ratio in this compartment is associated with worse PFS (P = 0.040) (B) and OS (P = 0.038) (C). Higher Lac/Cr ratio in the ADCH-rCBVL compartment is
associated with worse PFS (P = 0.025) (D).
22 Low Perfusion Compartments in GlioblastomaWe measured the lactate, macromolecule and lipid levels at
0.9 ppm (ML9) in the spectra, as increased lactate indicates an
acidic microenvironment, while ML9 is associated with pro-
inflammatory microglial response [31]. The elevated ML9/Cr ratiosmay suggest both compartments displayed elevated inflammation
response [31], potentially due to recruitment of inflammatory cells
by necrotic tissue [32]. The positive correlation between tumor
volume and lactate levels in the ADCL-rCBVL compartment could
C. Li et al. / Radiotherapy and Oncology 134 (2019) 17–24 23indicate a higher lactate production as tumor grows. When evalu-
ating the non-enhancing peritumoral regions, we found that
tumors with larger infiltration area tended to have smaller ADCH-
rCBVL and larger ADCL-rCBVL compartments, suggesting the latter
might be more responsible for infiltration. This was supported by
our findings that minimally invasive phenotypes displayed signifi-
cantly lower lactate in the ADCL-rCBVL compartment.
We further investigated the effects of two compartments on
patient survivals. Interestingly, a higher Lac/Cr ratio in the two
compartments was related to elevated hazard (HR > 1) while this
ratio in other tumor regions showed a reduced hazard. This implies
that the resistant phenotype may possibly reside in the two com-
partments. As the ADCL-rCBVL compartment was associated with
larger tumor infiltration area, higher diffusion invasiveness, and
the lactate level in this compartment had significant effect on both
PFS and OS, this compartment may be associated with treatment
resistance.
We found that higher volumes of both low perfusion compart-
ments were associated with better survivals, while higher Lac/Cr
ratios of these compartments were associated with worse sur-
vivals. These results suggested the higher proportion of the low
perfusion compartments may indicate relatively lower tumor pro-
liferation; the higher levels of lactate production in these compart-
ments, however, may indicate a more aggressive phenotype.
Consistent with our findings, previous studies showed that higher
levels of lactate production were associated with radioresistance
[33] and worse patient survival [34], potentially due to the antiox-
idative capacity of lactate.
Our findings have clinical significance. The identification of pos-
sibly resistant compartments could inform choice of treatment tar-
get. Our results show that higher acidic stress in ADCL-rCBVL
compartment may lead to a more aggressive phenotype. Since
adjuvant therapies may aggravate the microenvironmental stress,
this finding suggests that more attention may be needed for
patients with larger volumes of ADCL-rCBVL compartment.
There are limitations in our study. Firstly, due to the low
spatial resolution of MRSI, the multivariate analysis was based
on a subset of patients. The low spatial resolution of MRSI can
also affect the comparison of the metabolic signatures of the
two ADC-rCBV compartments. However, we have used a weight-
ing method to include multiple MRSI voxels containing the two
compartments, which may potentially help to reduce this bias
caused by a single voxel containing both compartments.
Secondly, the cut-off values defining the two compartments
were based on the quartiles of rCBV and ADC distributions in
individual lesion. We hypothesized that each individual tumor
can be an independent ecological system in which the selective
stress may arise from the disparities in sub-regional perfusion
and diffusion. Compared to our method, a global absolute
threshold across all patients may have the advantage of identify-
ing consistent tumor habitats among patients. Several limita-
tions, however, may still potentially exist when using the
absolute threshold, even if we have normalized all the pixel
values to the contralateral normal-appearing whiter matter. It
may not address our hypothesis of intratumoral habitats with
evolutionary disadvantages. More importantly, it could be signif-
icantly affected by the profound tumor heterogeneity and
limited by the scanning setting used in this specific cohort.
Thirdly, when the sequences of this study were designed, there
was still no consensus regarding the use of pre-bolus of contrast
agent. Therefore, a pre-bolus was not given in this study. How-
ever, to address this issue, we have used NordicICE to perform
leakage correction across all patients using the same software
setting. Lastly, although the imaging markers are validated histo-
logically from other studies [35], a full biological validation can
only be achieved with multi-region sampling of each tumor.In conclusion, we showed that multiparametric habitat imaging
could identify two low perfusion compartments, which may help
improve the non-specific conventional imaging. The compartment
demonstrating both low perfusion and restricted diffusion may
indicate a habitat especially responsible for treatment resistance.
This could provide crucial information for personalized treatment.
As our analyses were based on clinically available imaging modal-
ities, this approach could easily be implemented, and potentially
extended to other system.Conflict of interest
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